The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Open accessAbstract
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the response of HER2 mutant cancers to HER2 inhibition varies depending on the tissue-of-origin of the cancer84”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [84]
In the citing paper
“In concordance with this, clinical testing of afatinib, neratinib, and dacomitinib achieved overall response rates of 8.7%, 9.5%, and 12%, respectively, for patients harboring EGFR or HER2 exon 20 mutations25,42,46,47.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Cited by
Sorted by citations
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Network pharmacology: curing causal mechanisms instead of treating symptoms
Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,251
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,235
Self-citationTargeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,088
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L. A., Saltos, A. N., Felip, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,068
Self-citationThe Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 1,011
Self-citationPersonalized medicine: motivation, challenges, and progress
Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 637
Self-citationLi, B. T., Shen, R., Buonocore, D. J., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M. D., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 562
Self-citationRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Self-citationJavle, M. M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou‐Alfa, G. K., George, B., Hainsworth, J. D., Meric‐Bernstam, F., Swanton, C., Sweeney, C. J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00336-3 · Cited by 431
Self-citationEvolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 396
Turner, N. C., Kingston, B., Kilburn, L., Kernaghan, S., Wardley, A. M., Macpherson, I. R., Baird, R. D., Roylance, R. R., Stephens, P., Oikonomidou, O., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30444-7 · Cited by 376
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 372
Tsurutani, J., Iwata, H., Krop, I. E., Janne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C. H., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 359
Self-citationAdvances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Meric‐Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J. A., & Piha-Paul, S. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 348
Self-citationSignaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 338
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 332
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres‐Martín, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 309
Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0126 · Cited by 290
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S. G., Tu, H., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 293
Self-citationPersonalized Medicine: Recent Progress in Cancer Therapy
Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. M. R. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 301
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., Angelis, C. D., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 285
Meric‐Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J. A., Arkenau, H., Tran, B., Kelley, R. K., Park, J. O., Javle, M. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0697 · Cited by 262
Self-citationThe Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
Velden, D. L. V. D., Hoes, L. R., van der Wijngaart, H., Henegouwen, J. M. V. B., van Werkhoven, E. D., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1600-x · Cited by 260
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Bianchi, A. S., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F. M., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 254
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar, J. S., Gast, K. C., Quiroga, D. M., Lustberg, M. B., & Williams, N. O. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840984 · Cited by 261
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 258
Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Self-citationPrecision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 244
Peters, S., Stahel, R. A., Bubendorf, L., Bonomi, P., Villegas, A. E., Kowalski, D. M., Baik, C. S., Isla, D., de Castro, J., Garrido, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 237
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 232
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Self-citationNCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Benson, A. B., D'Angelica, M. I., Abrams, T. A., Abbott, D. E., Ahmed, A., Anaya, D. A., Anders, R. A., Are, C., Bachini, M., Binder, D. C., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0035 · Cited by 222
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C. J., Gao, G., Ng, T. L., Tu, M. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 210
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 210
HER2-targeted therapies in gastric cancer
Zhu, Y., Zhu, X., Wei, X., Tang, C., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188549 · Cited by 205
The NCI-MATCH trial: lessons for precision oncology
O'Dwyer, P. J., Gray, R. J., Flaherty, K. T., Chen, A. P., Li, S., Wang, V., McShane, L. M., Patton, D. R., Tricoli, J. V., Williams, P. M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02379-4 · Cited by 199
Self-citationAccelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
Riudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 202
Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 202
Weinberg, B. A., Xiu, J., Lindberg, M. R., Shields, A. F., Hwang, J. J., Poorman, K. A., Salem, M. E., Pishvaian, M. J., Holcombe, R. F., Marshall, J. L., et al. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.08.18 · Cited by 185
Next generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2018) · Cancer Science · doi:10.1111/cas.13837 · Cited by 183
Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
HER2-targeted therapies beyond breast cancer — an update
Yoon, J., & Oh, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00924-9 · Cited by 188
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., Cristoferi, L., Ciaccio, A., Cortinovis, D. L., Invernizzi, P., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100737 · Cited by 168
Genomics to select treatment for patients with metastatic breast cancer
André, F., Filleron, T., Kamal, M. T., Mosele, F., Arnedos, M., Dalenc, F., Sablin, M., Campone, M., Bonnefoi, H. R., Lefeuvre‐Plesse, C., et al. (2022) · Nature · doi:10.1038/s41586-022-05068-3 · Cited by 167
Tissue-specificity in cancer: The rule, not the exception
Haigis, K. M., Cichowski, K. M., & Elledge, S. J. (2019) · Science · doi:10.1126/science.aaw3472 · Cited by 167
Le, X., Cornelissen, R., Garassino, M. C., Clarke, J. M., Tchekmedyian, N., Goldman, J. W., Leu, S.-Y., Bhat, G., Lebel, F. M., Heymach, J. V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01323 · Cited by 169
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Pahuja, K. B., Nguyen, T. T., Jaiswal, B. S., Prabhash, K., Thaker, T. M., Senger, K., Chaudhuri, S., Kljavin, N. M., Antony, A., Phalke, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.010 · Cited by 167
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 162
Pegram, M. D., Jackisch, C., & Johnston, S. R. D. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00533-2 · Cited by 172
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Self-citationKim, S.-Y., Kim, S.-M., Lim, S., Lee, J. Y., Choi, S.-J., Yang, S.-D., Yun, M. R., Kim, C. G., Gu, S. R., Park, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5026 · Cited by 151
Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortés, J., Hyman, D., Juric, D., Krop, I. E., Bièche, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz036 · Cited by 154
Self-citationOncoTree: A Cancer Classification System for Precision Oncology
Kundra, R., Zhang, H., Sheridan, R., Sirintrapun, S. J., Wang, A., Ochoa, A., Wilson, M., Gross, B. E., Sun, Y., Madupuri, R., et al. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00108 · Cited by 150
Self-citationTowards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 154
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152
Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine
Rossi, G., & Ignatiadis, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3402 · Cited by 146
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 150
Zhang, G., Ren, C., Li, C., Wang, Y., Chen, B., Wen, L., Jia, M., Li, K., Mok, H., Cao, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02346-9 · Cited by 137
The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
Meyer, E. L., Mesenbrink, P. G., Dunger‐Baldauf, C., Fülle, H., Glimm, E., Li, Y., Posch, M., & König, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.010 · Cited by 141
Tsai, R. M., Miller, Z., KOESTLER, M. E., Rojas, J. C., Ljubenkov, P. A., Rosen, H. J., Rabinovici, G. D., Fagan, A. M., Cobigo, Y., Brown, J. A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3812 · Cited by 141
Kurzrock, R., Bowles, D. W., Kang, H., Meric‐Bernstam, F., Hainsworth, J. D., Spigel, D. R., Bose, R., Burris, H. A., Sweeney, C. J., Beattie, M. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.018 · Cited by 133
Self-citationLi, B. T., Meric‐Bernstam, F., Bardia, A., Naito, Y., Siena, S., Aftimos, P., Anderson, I., Curigliano, G., Miguel, M. J. D., Kalra, M., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00140-2 · Cited by 134
Self-citationDagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 141
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 129
Self-citationHER2-positive advanced breast cancer treatment in 2020
Cesca, M. G., Vian, L., Cristóvão‐Ferreira, S., Ponde, N. F., & de Azambuja, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102033 · Cited by 130
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C. J., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 134
Consensus for HER2 alterations testing in non-small-cell lung cancer
Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D., Wang, Z., Chu, Q., Mack, P. C., Cheng, Y., Duan, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100395 · Cited by 127
Precision medicine becomes reality—tumor type‐agnostic therapy
Li, Y., & Zhang, W. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0274-3 · Cited by 121
Varešlija, D., Priedigkeit, N., Fagan, A., Purcell, S. P., Cosgrove, N. S., O’Halloran, P. J., Ward, E., Cocchiglia, S., Hartmaier, R. J., Castro, C. A., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy110 · Cited by 124
Jin, J., Wu, X., Yin, J., Li, M., Shen, J., Li, J., Zhao, Y., Zhao, Q., Wu, J., Wen, Q., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00263 · Cited by 126
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 120
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 114
Self-citationOu, D., Sun, D., Lin, X., Liang, Z., Zhong, Y., & Chen, Z. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00472f · Cited by 112
Segers, V. F. M., Dugaucquier, L., Feyen, E., Shakeri, H., & Keulenaer, G. W. D. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00499-4 · Cited by 112
Clinicopathologic and Genomic Analysis of TP53 -Mutated Endometrial Carcinomas
Boroujeni, A. M., Dahoud, W., Vanderbilt, C., Chiang, S., Murali, R., Rios‐Doria, E., Alektiar, K. M., Aghajanian, C. A., Abu‐Rustum, N. R., Ladanyi, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4436 · Cited by 110
Self-citationERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Kiavué, N., Cabel, L., Melaabi, S., Bataillon, G., Callens, C., Lerebours, F., Pierga, J., & Bidard, F. (2019) · Oncogene · doi:10.1038/s41388-019-1001-5 · Cited by 109
Collins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. P. (2019) · Cancers · doi:10.3390/cancers11060737 · Cited by 115
Self-citationSmyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 109
Self-citationCroessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 107
Self-citationLongitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials
Staffaroni, A. M., Ljubenkov, P. A., Kornak, J., Cobigo, Y., Datta, S., Marx, G., Walters, S. M., Chiang, K., Olney, N., Elahi, F. M., et al. (2019) · Brain · doi:10.1093/brain/awy319 · Cited by 105
Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C. A., Akamatsu, H., Lee, K., Chatterjee, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 104
Self-citationLobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
Christgen, M., Cserni, G., Floris, G., Marchiò, C., Djerroudi, L., Kreipe, H. H., Derksen, P. W. B., & Vincent‐Salomon, A. (2021) · Cancers · doi:10.3390/cancers13153695 · Cited by 108
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 105
Molecular profiling and molecular classification of endometrioid ovarian carcinomas
Cybulska, P., Paula, A. D. C., Tseng, J. H., Leitão, M. M., Bashashati, A., Huntsman, D. D., Nazeran, T. M., Aghajanian, C. A., Abu‐Rustum, N. R., DeLair, D. F., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.07.012 · Cited by 101
Metadata
- Authors
- Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Vall d'Hebron Hospital Universitari (ES)
- Dana-Farber Cancer Institute (US)
- USC Norris Comprehensive Cancer Center (US)
- Vanderbilt University (US)
- Peter MacCallum Cancer Centre (AU)
- Washington University in St. Louis (US)
- Puma Biotechnology (United States) (US)
- Corresponding author
- Hyman, David M.
- ORCID
- Hyman, David M.
- Piha-Paul, Sarina A.
- Won, Helen
- Rodon, Jordi
- Saura, Cristina
- Shapiro, Geoffrey I.
- Juric, Dejan
- Quinn, David I.
- Mayer, Ingrid A.
- Boni, Valentina
- Calvo, Emiliano
- Loi, Sherene
- Lockhart, Albert C.
- Erinjeri, Joseph P.
- Scaltriti, Maurizio
- Ulaner, Gary A.
- Patel, Juber
- Bouvier, Nancy
- Murali, Rajmohan
- Schram, Alison M.
- Smyth, Lillian M.
- Jhaveri, Komal
- Li, Bob T.
- Drilon, Alexander
- Harding, James J.
- Iyer, Gopa
- Taylor, Barry S.
- Berger, Michael F.
- Xu, Feng
- Eli, Lisa D.
- Lalani, Alshad S.
- Bryce, Richard P.
- Arteaga, Carlos L.
- Solit, David B.
- Venue
- Nature
- Published
- 2018-01-31
- Volume
- 554
- Issue
- 7691
- Pages
- 189-194
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5808581
- OpenAlex
- W2785610956
- Cited by
- 780
- References
- 54
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-02-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Puma Biotechnology
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
